Conclusion on the Conformity of the Manufacturer of Drug Products for Medical Use with the Good Manufacturing Practices (GMP)
Shareholders
Pipeline
Media Center
-
mRNA non-vaccine therapeutics to generate $2 billion by 2028
09 December 2022
-
Vaccines Europe launches first pipeline review
08 December 2022
-
Could new 3D material advance drug delivery?
08 December 2022
-
About a third of pharma companies’ employees are planning to find a new job
07 December 2022